Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Adjunctive treatment with oral AKL1, a botanical nutraceutical, in chronic obstructive pulmonary disease.

Brockwell C, Ampikaipakan S, Sexton DW, Price D, Freeman D, Thomas M, Ali M, Wilson AM.

Int J Chron Obstruct Pulmon Dis. 2014 Jul 9;9:715-21. doi: 10.2147/COPD.S54276.

2.
3.

Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study.

Wang C, Sun T, Huang Y, Humphries M, Bai L, Li L, Wang Q, Kho P, Firth R, D'Andrea P.

Int J Chron Obstruct Pulmon Dis. 2015 Jan 5;10:57-68. doi: 10.2147/COPD.S72650. Erratum in: Int J Chron Obstruct Pulmon Dis. 2015;10:1513.

4.

Adjunctive Treatment with Rhodiola Crenulata in Patients with Chronic Obstructive Pulmonary Disease--A Randomized Placebo Controlled Double Blind Clinical Trial.

Chuang ML, Wu TC, Wang YT, Wang YC, Tsao TC, Wei JC, Chen CY, Lin IF.

PLoS One. 2015 Jun 22;10(6):e0128142. doi: 10.1371/journal.pone.0128142.

5.

Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.

Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B.

Clin Ther. 2011 Dec;33(12):1974-84. doi: 10.1016/j.clinthera.2011.11.009.

PMID:
22177371
6.

The validity and precision of the Leicester Cough Questionnaire in COPD patients with chronic cough.

Berkhof FF, Boom LN, ten Hertog NE, Uil SM, Kerstjens HA, van den Berg JW.

Health Qual Life Outcomes. 2012 Jan 9;10:4. doi: 10.1186/1477-7525-10-4.

8.

Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.

Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.

Clin Ther. 2012 Aug;34(8):1655-66.e5. doi: 10.1016/j.clinthera.2012.06.005.

PMID:
22789766
9.

Tiotropium and exercise training in COPD patients: effects on dyspnea and exercise tolerance.

Ambrosino N, Foglio K, Balzano G, Paggiaro PL, Lessi P, Kesten S; Tiotropium Multicentric Italian Study Group..

Int J Chron Obstruct Pulmon Dis. 2008;3(4):771-80.

10.

Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials.

Leidy NK, Murray LT, Monz BU, Nelsen L, Goldman M, Jones PW, Dansie EJ, Sethi S.

Respir Res. 2014 Oct 7;15:124. doi: 10.1186/s12931-014-0124-z.

11.

Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials.

Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, Gates D, Staudinger H.

Int J Chron Obstruct Pulmon Dis. 2012;7:73-86. doi: 10.2147/COPD.S29444.

12.

Anti-inflammatory effects of salmeterol/fluticasone propionate 50/250 mcg combination therapy in Japanese patients with chronic obstructive pulmonary disease.

Asai K, Kobayashi A, Makihara Y, Johnson M.

Int J Chron Obstruct Pulmon Dis. 2015 Apr 17;10:803-11. doi: 10.2147/COPD.S79842.

13.
14.

Validation of the French version of the Leicester Cough Questionnaire in chronic obstructive pulmonary disease.

Reychler G, Schinckus M, Fremault A, Liistro G, Pieters T.

Chron Respir Dis. 2015 Nov;12(4):313-9. doi: 10.1177/1479972315602618.

PMID:
26346891
15.

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.

D'Urzo AD, Rennard SI, Kerwin EM, Mergel V, Leselbaum AR, Caracta CF; AUGMENT COPD study investigators..

Respir Res. 2014 Oct 14;15:123. doi: 10.1186/s12931-014-0123-0.

16.

Ghrelin treatment of cachectic patients with chronic obstructive pulmonary disease: a multicenter, randomized, double-blind, placebo-controlled trial.

Miki K, Maekura R, Nagaya N, Nakazato M, Kimura H, Murakami S, Ohnishi S, Hiraga T, Miki M, Kitada S, Yoshimura K, Tateishi Y, Arimura Y, Matsumoto N, Yoshikawa M, Yamahara K, Kangawa K.

PLoS One. 2012;7(5):e35708. doi: 10.1371/journal.pone.0035708.

17.

CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.

Rennard SI, Dale DC, Donohue JF, Kanniess F, Magnussen H, Sutherland ER, Watz H, Lu S, Stryszak P, Rosenberg E, Staudinger H.

Am J Respir Crit Care Med. 2015 May 1;191(9):1001-11. doi: 10.1164/rccm.201405-0992OC.

PMID:
25695403
18.

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease.

Jones PW, Rennard SI, Agusti A, Chanez P, Magnussen H, Fabbri L, Donohue JF, Bateman ED, Gross NJ, Lamarca R, Caracta C, Gil EG.

Respir Res. 2011 Apr 26;12:55. doi: 10.1186/1465-9921-12-55.

19.

Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial.

Hanania NA, Boota A, Kerwin E, Tomlinson L, Denis-Mize K.

Drugs. 2009 Jun 18;69(9):1205-16. doi: 10.2165/00003495-200969090-00005.

PMID:
19537837
20.

Supplemental Content

Support Center